Boiron Past Earnings Performance
Past criteria checks 1/6
Boiron's earnings have been declining at an average annual rate of -7.6%, while the Pharmaceuticals industry saw earnings growing at 15.3% annually. Revenues have been declining at an average rate of 4.3% per year. Boiron's return on equity is 8.5%, and it has net margins of 9.2%.
Key information
-7.6%
Earnings growth rate
-6.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 16.3% |
| Revenue growth rate | -4.3% |
| Return on equity | 8.5% |
| Net Margin | 9.2% |
| Next Earnings Update | 11 Sep 2024 |
Recent past performance updates
Recent updates
Calculating The Intrinsic Value Of Boiron SA (EPA:BOI)
Jan 26
Boiron (EPA:BOI) Has Re-Affirmed Its Dividend Of €0.95
Apr 28Estimating The Intrinsic Value Of Boiron SA (EPA:BOI)
Jan 22Is Boiron SA's (EPA:BOI) 2.3% Dividend Worth Your Time?
Apr 30Boiron (EPA:BOI) Has A Pretty Healthy Balance Sheet
Apr 12Reflecting on Boiron's (EPA:BOI) Share Price Returns Over The Last Three Years
Mar 08A Look At The Intrinsic Value Of Boiron SA (EPA:BOI)
Feb 18
Does The Market Have A Low Tolerance For Boiron SA's (EPA:BOI) Mixed Fundamentals?
Feb 02Should You Buy Boiron SA (EPA:BOI) For Its Dividend?
Jan 19Does Boiron's (EPA:BOI) Statutory Profit Adequately Reflect Its Underlying Profit?
Dec 27What Kind Of Shareholders Hold The Majority In Boiron SA's (EPA:BOI) Shares?
Dec 14Revenue & Expenses BreakdownBeta
How Boiron makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 517 | 48 | 317 | 6 |
| 31 Mar 23 | 526 | 46 | 314 | 6 |
| 31 Dec 22 | 534 | 45 | 310 | 6 |
| 30 Sep 22 | 528 | 48 | 298 | 5 |
| 30 Jun 22 | 522 | 51 | 286 | 4 |
| 31 Mar 22 | 489 | 40 | 281 | 4 |
| 31 Dec 21 | 455 | 29 | 277 | 3 |
| 30 Sep 21 | 453 | 23 | 286 | 3 |
| 30 Jun 21 | 450 | 18 | 296 | 3 |
| 31 Mar 21 | 482 | 22 | 304 | 3 |
| 31 Dec 20 | 514 | 26 | 312 | 4 |
| 30 Sep 20 | 534 | 33 | 318 | 3 |
| 30 Jun 20 | 554 | 40 | 324 | 3 |
| 31 Mar 20 | 556 | 40 | 334 | 3 |
| 31 Dec 19 | 557 | 41 | 344 | 3 |
| 30 Sep 19 | 569 | 38 | 351 | 3 |
| 30 Jun 19 | 580 | 35 | 358 | 4 |
| 31 Mar 19 | 592 | 46 | 360 | 4 |
| 31 Dec 18 | 604 | 57 | 363 | 4 |
| 30 Sep 18 | 609 | 66 | 360 | 4 |
| 30 Jun 18 | 613 | 75 | 357 | 4 |
| 31 Mar 18 | 615 | 77 | 359 | 4 |
| 31 Dec 17 | 618 | 78 | 360 | 4 |
| 30 Sep 17 | 616 | 77 | 361 | 4 |
| 30 Jun 17 | 615 | 76 | 362 | 4 |
| 31 Mar 17 | 615 | 77 | 359 | 4 |
| 31 Dec 16 | 614 | 78 | 356 | 4 |
| 30 Sep 16 | 616 | 78 | 357 | 4 |
| 30 Jun 16 | 617 | 79 | 358 | 4 |
| 31 Mar 16 | 612 | 76 | 356 | 4 |
| 31 Dec 15 | 608 | 74 | 354 | 4 |
| 30 Sep 15 | 616 | 83 | 352 | 4 |
| 30 Jun 15 | 624 | 91 | 349 | 4 |
| 31 Mar 15 | 617 | 90 | 348 | 5 |
| 31 Dec 14 | 610 | 89 | 346 | 5 |
| 30 Sep 14 | 607 | 83 | 346 | 6 |
| 30 Jun 14 | 604 | 76 | 345 | 6 |
| 31 Mar 14 | 611 | 79 | 345 | 6 |
| 31 Dec 13 | 618 | 82 | 345 | 6 |
| 30 Sep 13 | 609 | 74 | 349 | 6 |
| 30 Jun 13 | 601 | 66 | 353 | 6 |
Quality Earnings: BOI has high quality earnings.
Growing Profit Margin: BOI's current net profit margins (9.2%) are lower than last year (9.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BOI's earnings have declined by 7.6% per year over the past 5 years.
Accelerating Growth: BOI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BOI had negative earnings growth (-5.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.5%).
Return on Equity
High ROE: BOI's Return on Equity (8.5%) is considered low.